Back to top
more

Allergan plc (AGN)

(Delayed Data from NYSE)

$145.81 USD

145.81
1,518,334

+1.56 (1.08%)

Updated May 3, 2019 04:01 PM ET

After-Market: $145.88 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Why Is Allergan (AGN) Down 4.1% Since its Last Earnings Report?

by Zacks Equity Research

Allergan (AGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Allergan Recalls Taytulla Oral Contraceptives, Stock Down

    by Zacks Equity Research

    Allergan (AGN) recalls some sample packs of Taytulla oral birth control pills. Shares decline.

      Allergan Stock Down Since Q1 Earnings Report: Here's Why

      by Zacks Equity Research

      Though Allergan (AGN) boasts a solid underlying business, its stock is down. Here we discuss why.

        Amgen's Label Expansion Application for Prolia Gets FDA Nod

        by Zacks Equity Research

        Amgen (AMGN) announces FDA approval for its regulatory application seeking label expansion for Prolia.

          BioDelivery (BDSI) Q1 Earnings and Sales Beat Estimates

          by Zacks Equity Research

          BioDelivery Sciences' (BDSI) reports narrower-than-expected loss in Q1. Sales marginally beat the consensus mark.

            Aerie (AERI) Incurs Lower Loss in Q1, Launches Rhopressa

            by Zacks Equity Research

            Aerie (AERI) reported a narrower-than-expected loss in the first quarter. The launch of the lead drug Rhopressa is underway.

              BioDelivery Sciences (BDSI) Q1 Earnings: What to Expect?

              by Zacks Equity Research

              Investor focus will be on the performance of BioDelivery Sciences' (BDSI) two marketed drugs, Belbuca (chronic pain) and Bunavail (opioid-dependence).

                Drug/Biotech Q1 Earnings Lineup on May 8: JAZZ, ARNA & More

                by Zacks Equity Research

                The pharma/biotech industry has witnessed a mixed first-quarter earnings picture so far. Let's see what's in store for some of the smaller players.

                  Teva (TEVA) Stock Dips Despite Q1 Earnings & Sales Beat

                  by Zacks Equity Research

                  Teva's (TEVA) shares dip despite first-quarter earnings and sales beat. The company raises its 2018 sales and earnings outlook.

                    Pharma Stock Roundup: Mixed Q1 for MRK, PFE, FDA Nod for Kymriah's 2nd Indication

                    by Zacks Equity Research

                    Earnings are in focus this week with Pfizer (PFE) and Merck (MRK) delivering mixed Q1 numbers. Novartis gains FDA approval for the second indication of its CAR-T therapy, Kymriah.

                      Ironwood (IRWD) Incurs Loss in Q1, Announces Restructuring

                      by Zacks Equity Research

                      Ironwood Pharmaceuticals (IRWD) misses estimates on both counts in the first quarter. The company will be separated into two entities for better management.

                        Stock Market News For May 1, 2018

                        by Zacks Equity Research

                        U.S. stock markets ended in negative territory on Monday as a broad-based decline pushed all three major indexes in red

                          Allergan (AGN) Q1 Earnings Beat Estimates, Sales Up Y/Y

                          by Zacks Equity Research

                          Allergan's (AGN) first-quarter 2018 earnings surpass estimates with revenues also marginally beating the same. Moreover, the company ups its adjusted earnings and sales view for the full year.

                            Allergan (AGN) Beats Q1 Earnings, Stock Up

                            by Zacks Equity Research

                            Allergan's (AGN) first-quarter 2018 earnings surpassed estimates with revenues marginally beating the same. The company also raised its adjusted earnings and sales guidance for 2018.

                              Why Earnings Season Could Be Great for Allergan (AGN)

                              by Zacks Equity Research

                              Allergan (AGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

                                Can Allergan (AGN) Keep the Earnings Streak Alive in Q1?

                                by Zacks Equity Research

                                While Allergan's (AGN) Q1 sales are likely to be driven by new as well as established products like Botox and international growth, generic competition for some key products is expected to hurt sales.

                                  Is SPDR S&P Pharmaceuticals ETF (XPH) a Hot ETF Right Now?

                                  by Zacks Equity Research

                                  Smart Beta ETF report for XPH

                                    Shire (SHPG) Turns Down Takeda's Third Buyout Proposition

                                    by Zacks Equity Research

                                    Shire (SHPG) declines Takeda Pharmaceutical's third acquisition offer in a cash-stock deal.

                                      Amgen (AMGN) to Report Q1 Earnings: Is a Beat in the Cards?

                                      by Zacks Equity Research

                                      While Amgen's (AMGN) growth drugs like Prolia & Xgeva might do well, biosimilar competition and slowdown in sales of mature products can put pressure on sales growth.

                                        Taye Baldinazzo headshot

                                        Why Is Allergan (AGN) Stock Falling Today?

                                        by Taye Baldinazzo

                                        Allergan (AGN) shares have fallen 5.8% on the day, while Shire plc (SHPG) is up 3.4% so far. These fluctuations come in light of a $50 billion dollar acquisition deal for Shire that is now taking a competitive turn.

                                          FDA Prolongs Review Date for AbbVie Endometriosis Candidate

                                          by Zacks Equity Research

                                          The FDA extends the review period of NDA for AbbVie (ABBV) and partner Neurocrine Biosciences' endometriosis candidate, elagolix, by three months to third-quarter 2018.

                                            Paratek's (PRTK) NDAs for Omadacycline Get Priority Review

                                            by Zacks Equity Research

                                            Paratek Pharmaceuticals (PRTK) is seeking approval for its antibiotic candidate, omadacycline, for the treatment of CABP and ABSSSI in the United States.

                                              FDA Refuses Alkermes Depression Drug Review: 4 Stocks in Focus

                                              by Zacks Equity Research

                                              The FDA's refusal to review Alkermes' depression candidate AKLS 5461 has brought depression disease market in focus. Here we take a look at a few companies developing products for this market.

                                                Allergan's Vraylar Meets Endpoints in Bipolar I Phase III

                                                by Zacks Equity Research

                                                Allergan (AGN) along with partner Gedeon Richter posts positive top-line results from the third pivotal study, analyzing label expansion of the schizophrenia drug Vraylar to cure bipolar I depression.

                                                  Biotech Stock Roundup: PTGX Down, VRNA Up, AMGN's Repatha Gets Positive Opinion

                                                  by Zacks Equity Research

                                                  The biotech sector was in focus last week with Protagonist's stock plunging on news of discontinuation of a phase IIb study and Verona Pharma stock surging on positive top-line data from COPD study among others.